Frank X Leonard $NVCR SEC Form 4 Insider Trading

Frank X Leonard has filed a total of 56 insider trades in $NVCR since 2021. Their most recent trade was a sale of 5,607 shares, made on Mar 04, 2026. Their largest trade was a sale of 21,717 shares, made on Jun 02, 2025. We estimate that they now own 493,793 shares of $NVCR, worth an estimated $4.7 million.

Insider Trading at $NVCR

There have been a total of 192 insider trades reported at $NVCR since 2021, with 106,524 shares purchased and 700,898 shares sold. The most active insider traders in $NVCR stock have been Frank X Leonard, Frank X Leonard, and Ashley Cordova. The most recent trade was a sale of 1,100 shares reported by Nicolas Leupin (Former Chief Medical Officer), made on Mar 04, 2026.

$NVCR Executives and Stock Owners with Insider Trades

• Frank X Leonard, Chief Development Officer

• Frank X Leonard, President, CNS Cancers US

• Ashley Cordova, Chief Financial Officer

• Asaf Danziger, Chief Executive Officer

• Wilhelmus Cm Groenhuysen, Chief Operating Officer

• Pritesh Shah, Chief Commercial Officer

• Frank X Leonard, EVP, Pres., Novocure Oncology

• William Patrick Burke, Chief Human Resources Officer

• Ely Benaim, Chief Medical Officer

• Mukund Paravasthu, Chief Operating Officer

• Pritesh Shah, Chief Growth Officer

• Michal Nath Puri, Chief Human Resources Officer

• Ashley Cordova, Chief Executive Officer

• Uri Weinberg, Chief Science Officer

• Christoph Brackmann, Chief Financial Officer

• Todd Christopher Longsworth, General Counsel

• Uri Weinberg, Chf Medical and Innovation Ofr

• William F Doyle, Executive Chairman

• Uri Weinberg, Chief Innovation Officer

• Nicolas Leupin, Chief Medical Officer

• Frank X Leonard, Chief Executive Officer

• Nicolas Leupin, Former Chief Medical Officer

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.